SINOMED(688108)2024-07-29 07:54Financial Performance - The company expects to achieve a net profit attributable to shareholders of 7.66 million yuan, an increase of 37.27 million yuan compared to the same period last year, representing a year-on-year growth of 125.88%[3]. - The estimated operating income for the reporting period is 213.69 million yuan, an increase of 52.41 million yuan, which corresponds to a year-on-year growth of 32.49%[10]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be -12.59 million yuan, an improvement of 22.39 million yuan compared to the previous year, reflecting a year-on-year growth of 64.00%[11]. Revenue Growth - The coronary intervention business is expected to see a revenue increase of 70.77%, with projected revenue of 122.45 million yuan due to the implementation of the national centralized procurement policy[5]. - The neuro-intervention business is expected to grow by 2.74%, with projected revenue of 90.70 million yuan, an increase of 2.74% year-on-year[6]. - The company has experienced a significant increase in sales volume of balloon and stent products, leading to a decrease in unit product costs[6]. Investment and Expenses - The company anticipates a significant increase in investment income due to the acquisition of a controlling stake in Elum, with the fair value adjustment of 18.18% equity contributing to this growth[7]. - The company expects a year-on-year increase in research and development expenses due to the addition of new projects and milestones reached[6]. - Management expenses are expected to decrease year-on-year, attributed to the formal production of the subsidiary Sainuo Shenchang starting in Q2 2023[6]. Profitability Outlook - The overall increase in operating income is expected to outpace the growth in operating costs and sales expenses, contributing to improved profitability[13].